Human monoclonal antibodies against programmed death 1 (PD-1) and the method feeder to treat cancer by using anti-PD-1 antibodies alone or in combination with other immunterapeutika

SUMMARY The present invention relates to isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods of using a combination therapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease such as cancer. The invention also provides methods for changing negative events related to treatment with such antibodies individually.